CompletedNot Applicable

Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)

South Korea977 participantsStarted 2019-01-02

Plain-language summary

The goal of this multicenter prospective clinical cohort study is to investigate the impact of early use of low-dose Ticagrelor-based dual antiplatelet agent therapy (TDAPT) (ticagrelor 120mg daily; l-TDAPT) as compared to standard-dose TDAPT (ticagrelor 180mg daily; s-TDAPT) in outcomes of percutaneous coronary intervention (PCI). The main question it aims to answer are: Given the low ischemic risk and high bleeding tendency in Asians, the low dose TDAPT may provide better net clinical benefits of ischemic and bleeding events than the standard dose TDAPT.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 19 years of age or older * acute coronary syndrome (ACS) undergoing PCI * PCI for complex coronary lesions using everolimus-eluting stents (Xience®, Abbot corp, Chicago, Illinois, US) * prescribed with s-TDAPT for more than 3 months Exclusion Criteria: * cardiogenic shock * PCI using drug-eluting stents (DES) other than the everolimus-eluting stents * those who had conditions requiring a long-term oral anticoagulant therapy * those with life expectancy \<1 year

What they're measuring

A major adverse cardiac and cerebrovascular event (MACE)

Timeframe: at 1 years after discharge

Trial details

NCT IDNCT05746416

SponsorHanyang University Seoul Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12-31

View on ClinicalTrials.gov More Coronary Artery Disease trials